QR code

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking

Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The <i>BRCA1/2</i> genes and mutations in many additional genes involved in the HR pathway may be responsible for the HRD ph...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Aikaterini Tsantikidi, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, George Kapetsis, Georgios Tsaousis, Angeliki Meintani, Chrysiida Florou-Chatzigiannidou, Maria Gazouli, Christos Papadimitriou, Eleni Timotheadou, Athanasios Kotsakis, Anastasios Boutis, Ioannis Boukovinas, Eleftherios Kampletsas, Loukas Kontovinis, Elena Fountzilas, Charalampos Andreadis, Charisios Karanikiotis, Dimitrios Filippou, Georgios Theodoropoulos, Mustafa Özdoğan, George Nasioulas
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI AG 2023-09-01
Reeks:Diagnostics
Onderwerpen:
DNA repair
homologous recombination deficiency
biomarkers
precision oncology
loss of heterozygosity
poly (ADP-ribose) polymerase (PARP) inhibitors
Online toegang:https://www.mdpi.com/2075-4418/13/18/2962
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items